Clinical trial · Observational
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
NCT07021911CI-TRIAL-00091032COMBaRTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Radiotherapy; Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- ADC's group
- description
- Patients undergoing ADC's drugs such as Trastuzumab Emtansine (TDM1), Trastuzumab Deruxtecan, Sacituzumab Govitecan
- interventionNames
- Radiation: Radiotherapy
- label
- Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6 group)
- description
- Patients receiving Palbociclib or Ribociclib or Abemaciclib
- interventionNames
- Radiation: Radiotherapy
- label
- Anti Human Epidermal Growth Factor Receptor 2 monoclonal antibodies (Anti-Her2 group)
- description
- Patients receiving Trastuzumab or Trastuzumab Pertuzumab
- interventionNames
- Radiation: Radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients suffering from stage IV breast cancer * Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors) * Candidates for radiation treatment (both palliative and curative). Exclusion Criteria: * Previous radiation treatment on the same site * Absolute contraindications to radiotherapy * Systemic treatment administered as part of a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.